Market Overview

Celsion Announces Zhejiang HISUN Pharmaceutical does Not Plan to Pursue Exclusive Option to License ThermoDox for China

Celsion Corporation (NASDAQ: CLSN) today announced that Zheijang HISUN Pharmaceutical Company (HISUN) does not plan to pursue the exclusive option to license ThermoDox® for the Greater China market. Accordingly, the parties will not enter into the exclusive license agreement, and Celsion will not receive nor will it require any future payment for the option or license, as contemplated in the Exclusive Option Agreement announced on January 22, 2013. Celsion and HISUN have agreed that the Technology Development Contract entered into on January 18, 2013 will remain in effect while the parties continue to collaborate and are evaluating next steps in relation to ThermoDox®, which include the sub-group analysis of the Chinese cohort of patients in the Phase III Heat Study for the hepatocellular carcinoma clinical indication and other activities to further the development of ThermoDox® for the Greater China market . 

Celsion also announced that its proprietary patent application, "Method of

See full press release

Posted-In: News Guidance Contracts Management Global

 

Most Popular

Related Articles (CLSN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free